Who are BR1400-3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DAS181 COVID-19, BR1018B-1, BR1019B-1, Sacubitril / Valsartan Oral Tablet [Entresto], DAS181 OL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/br1400-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BR1400-3 — Competitive Intelligence Brief

BR1400-3 (BR1400-3) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE2 inhibitor. Area: Cardiovascular.

phase 2 ACE2 inhibitor ACE2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

BR1400-3 (BR1400-3) — Boryung Pharmaceutical Co., Ltd. BR1400-3 is a small molecule that targets the renin-angiotensin system.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BR1400-3 TARGET	BR1400-3	Boryung Pharmaceutical Co., Ltd	phase 2	ACE2 inhibitor	ACE2
DAS181 COVID-19	DAS181 COVID-19	Ansun Biopharma, Inc.	phase 3	ACE2 receptor decoy / recombinant fusion protein	SARS-CoV-2 spike protein (via ACE2 binding domain)
BR1018B-1	BR1018B-1	Boryung Pharmaceutical Co., Ltd	phase 3	ACE2 inhibitor	ACE2
BR1019B-1	BR1019B-1	Boryung Pharmaceutical Co., Ltd	phase 3	ACE2 inhibitor	ACE2
Sacubitril / Valsartan Oral Tablet [Entresto]	Sacubitril / Valsartan Oral Tablet [Entresto]	University Hospital, Grenoble	phase 3	ACE2 activator and angiotensin II receptor antagonist	ACE2 and AT1R
DAS181 OL	DAS181 OL	Ansun Biopharma, Inc.	phase 3	Recombinant fusion protein / Antiviral	ACE2 receptor domain (viral spike protein binding)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE2 inhibitor class)

Boryung Pharmaceutical Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BR1400-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/br1400-3. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab